Neuromod Devices Raises $12M to Revolutionize Bi-Modal Neuromodulation for Chronic Tinnitus Treatment

Neuromod Devices is excited to announce a successful funding round in which the company raised $12,000,000, a milestone that will propel its mission to revolutionize the treatment of chronic, debilitating conditions. As a pioneering medical device company, Neuromod is dedicated to advancing the science of bi-modal neuromodulation—a breakthrough that combines targeted therapies to address complex neurological disorders. The funds raised will be strategically deployed to intensify research and development efforts around Neuromod’s patented bi-modal neuromodulation technology, which is currently being evaluated for its ability to offer relief for patients suffering from chronic tinnitus. Tinnitus, affecting approximately 10% of the adult population, has long been a pervasive and challenging condition, often referred to as 'ringing in the ears.' This financial boost not only substantiates the unique innovation behind Neuromod’s technology but also reinforces the company’s commitment to creating treatments that significantly reduce the suffering of underserved patient populations across the globe. By focusing on designing products that empower individuals to take control of their own treatment, Neuromod is setting the stage for a paradigm shift in neurological care—one that integrates seamlessly into modern lifestyles with minimal disruption. This funding round marks a pivotal step in the journey towards alleviating the burden of neurological disorders while fostering a future where technologically advanced therapies bring hope and relief to millions. With continued investment in robust clinical studies and the pursuit of regulatory approvals, Neuromod Devices is poised to make a lasting impact on patient care worldwide.